Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Toripalimab or placebo with chemotherapy as initial therapy for advanced nasopharyngeal carcinoma in a multicenter, randomized phase 3 trial

  • By

  • Hai-Qiang Mai

  • Qiu-Yan Chen

  • Dongping Chen

  • Chaosu Hu

  • Kunyu Yang

  • Jiyu Wen

  • Jingao Li

  • Ying-Rui Shi

  • Feng Jin

  • Ruilian Xu

  • Jianji Pan

  • Shenhong Qu

  • Ping Li

  • Chunhong Hu

  • Yi-Chun Liu

  • Yi Jiang

  • Xia He

  • Hung-Ming Wang

  • Wan-Teck Lim

  • Wangjun Liao

  • Xiaohui He

  • Xiaozhong Chen

  • Zhigang Liu

  • Xianglin Yuan

  • Qi Li

  • Xiaoyan Lin

  • Shanghua Jing

  • Yanju Chen

  • Yin Lu

  • Ching-Yun Hsieh

  • Muh-Hwa Yang

  • Chia-Jui Yen

  • Jens Samol

  • Hui Feng

  • Sheng Yao

  • Patricia Keegan

  • Rui-Hua Xu

  • October 27, 2026

Share

  • 1

    The correction updates the number continuing maintenance treatment after chemotherapy to 233 (80.6%), replacing 231 (79.9%).

  • 2

    The data cutoff date for Fig. 2 is corrected to 18 February 2021, and its Source Data column label is corrected from “PFS” to “OS.”.

  • 3

    Table 3 corrections report 92 (63.0) for any-grade thrombocytopenia and 2 (1.4) for grade ≥3 hypochloremia in the toripalimab plus GP group.

  • 4

    The Supplementary Table S10 footnote now says “determined by BIRC,” and Supplementary Table S13 reports 219 (75.8) patients as alive.

  • 5

    The correction clarifies that 0 denotes an event and 1 denotes censoring in specified Source Data, and that three patients were censored under prespecified PFS and duration-of-response rules; study re

Original Source(s)

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

  • by Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu, Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui-Hua Xu

  • October 27, 2026

Related Content

Bayesian network meta-analysis comparing efficacy of surgical gastrojejunostomy, endoscopic stenting, and EUS-guided gastroenterostomy for malignant gastric outlet obstruction

The Evidence-Based Cancer Control Programs website – a strategy for disseminating effective interventions

Revised Meta-Analysis After Exclusion of Retracted Study

  • October 21, 2026